Published in Expert Rev Proteomics on August 01, 2010
Loss of a 20S proteasome activator in Saccharomyces cerevisiae downregulates genes important for genomic integrity, increases DNA damage, and selectively sensitizes cells to agents with diverse mechanisms of action. G3 (Bethesda) (2012) 0.84
Protein mislocalization: mechanisms, functions and clinical applications in cancer. Biochim Biophys Acta (2014) 0.76
A proteomic approach to obesity and type 2 diabetes. J Cell Mol Med (2015) 0.76
Structural insights into the folding defects of oncogenic pVHL lead to correction of its function in vitro. PLoS One (2013) 0.76
The role of the proteasome in AML. Blood Cancer J (2016) 0.75
Reproducible enrichment of extracellular heat shock proteins from blood serum using monomeric avidin. Bioorg Med Chem Lett (2011) 0.75
TOR signaling in growth and metabolism. Cell (2006) 35.29
Defining the role of mTOR in cancer. Cancer Cell (2007) 21.63
Protein folding and misfolding. Nature (2003) 14.92
HSP90 and the chaperoning of cancer. Nat Rev Cancer (2005) 11.98
mTOR and cancer: insights into a complex relationship. Nat Rev Cancer (2006) 11.86
Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell (2002) 11.59
Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol (1997) 11.36
p53 in health and disease. Nat Rev Mol Cell Biol (2007) 11.33
The roles of intracellular protein-degradation pathways in neurodegeneration. Nature (2006) 9.77
Hsp70 chaperones: cellular functions and molecular mechanism. Cell Mol Life Sci (2005) 9.75
The TOR pathway: a target for cancer therapy. Nat Rev Cancer (2004) 9.02
Comparison of label-free methods for quantifying human proteins by shotgun proteomics. Mol Cell Proteomics (2005) 8.14
Molecular chaperones and protein quality control. Cell (2006) 7.74
A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature (2003) 7.69
A renaissance for SRC. Nat Rev Cancer (2004) 6.27
The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat Cell Biol (2001) 6.10
Folding of newly translated proteins in vivo: the role of molecular chaperones. Annu Rev Biochem (2001) 5.74
The pharmacology of mTOR inhibition. Sci Signal (2009) 5.36
Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones (2005) 5.22
Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis (1997) 5.06
Identification of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions. Mol Cell Biol (1999) 4.98
Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev (2003) 4.62
Therapeutic approaches to protein-misfolding diseases. Nature (2003) 4.57
Disassembly of transcriptional regulatory complexes by molecular chaperones. Science (2002) 4.20
Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci (2006) 4.04
Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol (2008) 3.85
Stress and mTORture signaling. Oncogene (2006) 3.84
Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol (2005) 3.42
Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. J Biol Chem (2007) 3.42
Role of Src expression and activation in human cancer. Oncogene (2000) 3.41
Structural biology of the tumor suppressor p53. Annu Rev Biochem (2008) 3.36
The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J (2008) 3.33
The ribosome as a platform for co-translational processing, folding and targeting of newly synthesized proteins. Nat Struct Mol Biol (2009) 3.21
CHIP: a link between the chaperone and proteasome systems. Cell Stress Chaperones (2003) 2.98
Heat-shock protein hsp90 governs the activity of pp60v-src kinase. Proc Natl Acad Sci U S A (1993) 2.92
Genome-wide RNA interference screen identifies previously undescribed regulators of polyglutamine aggregation. Proc Natl Acad Sci U S A (2004) 2.89
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol (2007) 2.80
Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy. J Leukoc Biol (2006) 2.79
Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol (2005) 2.70
Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol (2008) 2.65
The development of the DIGE system: 2D fluorescence difference gel analysis technology. Anal Bioanal Chem (2005) 2.64
A small molecule inhibitor of inducible heat shock protein 70. Mol Cell (2009) 2.63
Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell (2008) 2.49
Update on Hsp90 inhibitors in clinical trial. Curr Top Med Chem (2009) 2.34
Heat shock proteins as emerging therapeutic targets. Br J Pharmacol (2005) 2.25
Search for cancer markers from endometrial tissues using differentially labeled tags iTRAQ and cICAT with multidimensional liquid chromatography and tandem mass spectrometry. J Proteome Res (2005) 2.22
The carboxy-terminal domain of Hsc70 provides binding sites for a distinct set of chaperone cofactors. Mol Cell Biol (1998) 2.05
On mechanisms that control heat shock transcription factor activity in metazoan cells. Cell Stress Chaperones (2004) 2.03
Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach. Hum Mol Genet (2004) 2.00
Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin. Cancer Res (2005) 1.93
Development and application of Hsp90 inhibitors. Drug Discov Today (2007) 1.91
Hsp70 molecular chaperones: emerging roles in human disease and identification of small molecule modulators. Curr Top Med Chem (2006) 1.77
Targeting HSP70: the second potentially druggable heat shock protein and molecular chaperone? Cell Cycle (2010) 1.75
The role of Src in solid tumors. Oncologist (2009) 1.72
Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat Med (1997) 1.68
Maturation of the tyrosine kinase c-src as a kinase and as a substrate depends on the molecular chaperone Hsp90. Proc Natl Acad Sci U S A (1999) 1.66
Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res (2007) 1.66
Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Oncogene (2007) 1.62
The von Hippel-Lindau tumor suppressor protein. Curr Opin Genet Dev (2001) 1.61
The cell line secretome, a suitable tool for investigating proteins released in vivo by tumors: application to the study of p53-modulated proteins secreted in lung cancer cells. J Proteome Res (2009) 1.58
Pharmacological targeting of the Hsp70 chaperone. Curr Top Med Chem (2009) 1.51
The ubiquitin ligase CHIP acts as an upstream regulator of oncogenic pathways. Nat Cell Biol (2009) 1.51
Targeting HSP90 for cancer therapy. Br J Cancer (2009) 1.44
Heat shock protein 70 is required for the survival of cancer cells. Ann N Y Acad Sci (2000) 1.44
Requirement of the mTOR kinase for the regulation of Maf1 phosphorylation and control of RNA polymerase III-dependent transcription in cancer cells. J Biol Chem (2010) 1.42
Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism. Cancer Res (2006) 1.42
17 AAG for HSP90 inhibition in cancer--from bench to bedside. Curr Mol Med (2009) 1.40
Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations. EMBO J (2000) 1.38
Discovery and development of heat shock protein 90 inhibitors. Bioorg Med Chem (2008) 1.36
A proteomic snapshot of the human heat shock protein 90 interactome. FEBS Lett (2005) 1.33
Targeting Hsp90 for the treatment of cancer. Curr Opin Drug Discov Devel (2006) 1.32
Geldanamycin induces Hsp70 and prevents alpha-synuclein aggregation and toxicity in vitro. Biochem Biophys Res Commun (2004) 1.30
To fold or not to fold: modulation and consequences of Hsp90 inhibition. Future Med Chem (2009) 1.29
Novel subunits of the mammalian Hsp90 signal transduction chaperone. J Proteome Res (2007) 1.29
New tricks for an old dog: the evolving world of Hsp70. Ann N Y Acad Sci (2007) 1.27
Hsp90 chaperones wild-type p53 tumor suppressor protein. J Biol Chem (2004) 1.27
Anti-cancer therapeutic approaches based on intracellular and extracellular heat shock proteins. Curr Med Chem (2007) 1.26
Diverse proteomic alterations in gastric adenocarcinoma. Proteomics (2004) 1.24
Folding of a nascent peptide on the ribosome. Prog Nucleic Acid Res Mol Biol (2001) 1.23
Hsp90 is essential for the synthesis and subsequent membrane association, but not the maintenance, of the Src-kinase p56(lck). Mol Biol Cell (2000) 1.22
Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases. Cancer Res (2000) 1.21
Novel therapeutic strategies for the treatment of protein-misfolding diseases. Expert Rev Mol Med (2007) 1.18
The unfolded protein response during prostate cancer development. Cancer Metastasis Rev (2009) 1.18
CRINEPT-TROSY NMR reveals p53 core domain bound in an unfolded form to the chaperone Hsp90. Proc Natl Acad Sci U S A (2002) 1.17
Clinical and biological significance of HSP89 alpha in human breast cancer. Int J Cancer (1992) 1.14
Loss of function and p53 protein stabilization. Oncogene (1997) 1.14
Recent advances in Wilms tumor genetics. Curr Opin Pediatr (2002) 1.13
Bridging the gap: from protein misfolding to protein misfolding diseases. FEBS Lett (2009) 1.13
A proteomic investigation of ligand-dependent HSP90 complexes reveals CHORDC1 as a novel ADP-dependent HSP90-interacting protein. Mol Cell Proteomics (2009) 1.11
High constitutive expression of heat shock protein 90 alpha in human acute leukemia cells. Leuk Res (1992) 1.10
Novel Hsp90 partners discovered using complementary proteomic approaches. Cell Stress Chaperones (2009) 1.09
A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431. Proteomics (2004) 1.05
The neurofibromatosis type 2 gene product, merlin, reverses the F-actin cytoskeletal defects in primary human Schwannoma cells. Mol Cell Biol (2002) 1.04
The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors. Exp Hematol (2008) 1.04
Proteomics-based identification of autoantibody against heat shock protein 70 as a diagnostic marker in esophageal squamous cell carcinoma. Cancer Lett (2008) 1.00
Oncogenic mutations reduce the stability of SRC kinase. J Mol Biol (2004) 0.99
The novel HSP90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma cell lines. Int J Cancer (2009) 0.99
A proteomic approach towards the Hsp90-dependent ubiquitinylated proteome. Proteomics (2007) 0.98
Proteomics in cancer. Adv Clin Chem (2007) 0.98
Heat shock protein 90 associates with monarch-1 and regulates its ability to promote degradation of NF-kappaB-inducing kinase. J Immunol (2007) 0.97
Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology (2009) 4.08
Factors influencing readmission after pancreaticoduodenectomy: a multi-institutional study of 1302 patients. Ann Surg (2012) 2.93
Laparoscopic versus open left pancreatectomy: can preoperative factors indicate the safer technique? Ann Surg (2011) 2.87
Left-sided pancreatectomy: a multicenter comparison of laparoscopic and open approaches. Ann Surg (2008) 2.80
Perioperative blood transfusion is associated with decreased survival in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma: a multi-institutional study. J Gastrointest Surg (2014) 2.15
Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol (2008) 2.15
Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw (2012) 1.97
A multicenter analysis of distal pancreatectomy for adenocarcinoma: is laparoscopic resection appropriate? J Am Coll Surg (2010) 1.83
Proteome analysis of human colon cancer by two-dimensional difference gel electrophoresis and mass spectrometry. Proteomics (2004) 1.82
Polycyclic aromatic hydrocarbons: environmental pollution and bioremediation. Trends Biotechnol (2002) 1.77
Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis. Mol Cancer Ther (2010) 1.67
Molecular imaging of therapeutic response to epidermal growth factor receptor blockade in colorectal cancer. Clin Cancer Res (2008) 1.66
Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth. Clin Cancer Res (2011) 1.55
Vein involvement during pancreaticoduodenectomy: is there a need for redefinition of "borderline resectable disease"? J Gastrointest Surg (2013) 1.52
Urine PGE-M: A metabolite of prostaglandin E2 as a potential biomarker of advanced colorectal neoplasia. Clin Gastroenterol Hepatol (2006) 1.32
High-dimensional biology to comprehend hepatocellular carcinoma. Expert Rev Proteomics (2008) 1.17
Analysis of 6,747 pancreatic neuroendocrine tumors for a proposed staging system. J Gastrointest Surg (2010) 1.14
Src-mediated regulation of E-cadherin and EMT in pancreatic cancer. Front Biosci (Landmark Ed) (2012) 1.13
Standardization of surgical and pathologic variables is needed in multicenter trials of adjuvant therapy for pancreatic cancer: results from the ACOSOG Z5031 trial. Ann Surg Oncol (2010) 1.00
Endoscopic ultrasound and computed tomography predictors of pancreatic cancer resectability. J Gastrointest Surg (2007) 0.99
Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association. Radiology (2014) 0.98
Multi-institutional analysis of pancreatic adenocarcinoma demonstrating the effect of diabetes status on survival after resection. HPB (Oxford) (2012) 0.98
Emerging targets in pancreatic cancer: epithelial-mesenchymal transition and cancer stem cells. Onco Targets Ther (2013) 0.97
Novel mechanistic insights into ectodomain shedding of EGFR Ligands Amphiregulin and TGF-α: impact on gastrointestinal cancers driven by secondary bile acids. Cancer Res (2014) 0.95
Serum HSP70: a novel biomarker for early detection of pancreatic cancer. Pancreas (2012) 0.95
Weedy lignocellulosic feedstock and microbial metabolic engineering: advancing the generation of 'Biofuel'. Appl Microbiol Biotechnol (2010) 0.95
Diallyl disulfide causes caspase-dependent apoptosis in human cancer cells through a Bax-triggered mitochondrial pathway. J Nutr Biochem (2009) 0.94
Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the society of abdominal radiology and the american pancreatic association. Gastroenterology (2014) 0.90
Radiation-resistant extremophiles and their potential in biotechnology and therapeutics. Appl Microbiol Biotechnol (2012) 0.90
Gastric schwannoma. Am Surg (2008) 0.87
Organic anion transporting polypeptide 1B3 (OATP1B3) is overexpressed in colorectal tumors and is a predictor of clinical outcome. Clin Exp Gastroenterol (2008) 0.85
Ultra-structural mapping of sugarcane bagasse after oxalic acid fiber expansion (OAFEX) and ethanol production by Candida shehatae and Saccharomyces cerevisiae. Biotechnol Biofuels (2013) 0.84
Synchronous bone marrow metastasis from primary splenic angiosarcoma. Am Surg (2010) 0.84
Intensity of follow-up after pancreatic cancer resection. Ann Surg Oncol (2013) 0.83
Commentary: The role of global surgery electives during residency training: relevance, realities, and regulations. Surgery (2012) 0.83
Clinical evaluation, imaging studies, indications for cytologic study, and preprocedural requirements for duct brushing studies and pancreatic FNA: the Papanicolaou Society of Cytopathology recommendations for pancreatic and biliary cytology. Diagn Cytopathol (2014) 0.82
A clinical comparative analysis of crush/clamp, stapler, and dissecting sealer hepatic transection methods. HPB (Oxford) (2008) 0.82
Terminal ileal carcinoid tumor without hepatic or extrahepatic metastasis causing carcinoid syndrome. Am Surg (2013) 0.82
Trends in the use of evidence-based therapy for resectable gastric cancer. J Surg Oncol (2014) 0.81
Bioconversion of novel substrate Saccharum spontaneum, a weedy material, into ethanol by Pichia stipitis NCIM3498. Bioresour Technol (2010) 0.81
Value of intraoperative neck margin analysis during Whipple for pancreatic adenocarcinoma: a multicenter analysis of 1399 patients. Ann Surg (2014) 0.81
Granulocyte colony stimulating factor secreting hepatocellular carcinoma. Am Surg (2012) 0.80
Postbrushing and fine-needle aspiration biopsy follow-up and treatment options for patients with pancreatobiliary lesions: the Papanicolaou Society of Cytopathology guidelines. Diagn Cytopathol (2014) 0.80
Lymph node ratio and preoperative CA 19-9 levels predict overall survival and recurrence-free survival in patients with resected pancreatic adenocarcinoma. World J Gastrointest Oncol (2012) 0.80
Administration of oxaliplatin to a pregnant woman with rectal cancer. Cancer Chemother Pharmacol (2008) 0.80
Applications of proteomic technologies for understanding the premature proteolysis of CFTR. Expert Rev Proteomics (2010) 0.80
Incidence of additional primary malignancies in patients with pancreatic and gastrointestinal neuroendocrine tumors. Ann Surg Oncol (2014) 0.79
53BP1 expression is a modifier of the prognostic value of lymph node ratio and CA 19-9 in pancreatic adenocarcinoma. BMC Cancer (2013) 0.79
Development of more potent 4-dimethylaminopyridine analogues. Org Lett (2007) 0.79
Genomics and proteomics in predicting cancer outcomes. Surg Oncol Clin N Am (2008) 0.79
Optical Imaging of Drug-Induced Metabolism Changes in Murine and Human Pancreatic Cancer Organoids Reveals Heterogeneous Drug Response. Pancreas (2016) 0.79
Improvement of survival with response to neoadjuvant radiation therapy for rectal cancer. Arch Surg (2009) 0.79
Diagnostic and therapeutic implications of a novel immunohistochemical panel detecting duodenal mucosal invasion by pancreatic ductal adenocarcinoma. Int J Clin Exp Pathol (2013) 0.79
Bioremediation of radionuclides: emerging technologies. OMICS (2007) 0.78
Emergence of antibiotic-resistant extremophiles (AREs). Extremophiles (2012) 0.78
Bioconversion of Saccharum spontaneum (wild sugarcane) hemicellulosic hydrolysate into ethanol by mono and co-cultures of Pichia stipitis NCIM3498 and thermotolerant Saccharomyces cerevisiae-VS₃. N Biotechnol (2010) 0.78
Four jointed box 1 promotes angiogenesis and is associated with poor patient survival in colorectal carcinoma. PLoS One (2013) 0.76
Ultraviolet-radiation-resistant isolates revealed cellulose-degrading species of Cellulosimicrobium cellulans (UVP1) and Bacillus pumilus (UVP4). Biotechnol Appl Biochem (2012) 0.76
Asymmetric Synthesis of (+)-Iso-6-Cassine via Stereoselective Intramolecular Amidomercuration. Tetrahedron Lett (2007) 0.76
Using genomics to develop novel antibacterial therapeutics. Crit Rev Microbiol (2010) 0.76
Ir(I)-catalyzed enantioselective decarboxylative allylic etherification: a general method for the asymmetric synthesis of aryl allyl ethers. Org Lett (2013) 0.76
Integrating genomics and proteomics-oriented biomarkers to comprehend lung cancer. Expert Opin Med Diagn (2009) 0.76
Bioremediation: a genuine technology to remediate radionuclides from the environment. Microb Biotechnol (2013) 0.75
Appendiceal adenocarcinoma presenting as venous thromboembolism: an unusual presentation of a rare carcinoma. Am Surg (2010) 0.75
Surgical care and career opportunities in a changing practice paradigm. J Am Coll Surg (2013) 0.75